ArticleJournal of clinical medicine research2026
Spatial SRY-Box Transcription Factor 2 Expression and Stemness-Associated Markers Refine Risk Stratification in Barrett's Esophagus: A Digital Pathology Study of 217 Patients.
Article in Journal of clinical medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Barrett's esophagus (BE) is a precursor lesion of esophageal adenocarcinoma (EAC), but current risk stratification remains largely dependent on dysplasia grade and segment length. We investigated whether spatial SRY-box transcription factor 2 (SOX2) expression patterns could improve prediction of neoplastic progression in BE. Methods: This retrospective multicenter study included 217 patients with reflux esophagitis, non-dysplastic BE (NDBE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), or intramucosal EAC (EAC_T1a). Immunohistochemistry for SOX2, cluster of differentiation 44 (CD44), E-cadherin, p53, Ki-67 proliferation antigen (Ki67), and caudal-type homeobox transcription factor 2 (CDX2) was performed on formalin-fixed paraffin-embedded tissue. SOX2 expression was evaluated at the squamo-columnar junction and in deep Barrett glands, and a SOX2 gradient was calculated. Digital image analysis was used to assess SOX2 spatial heterogeneity and SOX2/CD44 co-localization. Associations with progression were analyzed using non-parametric tests and logistic regression models. Results: Progressive dysplastic transformation was associated with inversion of the SOX2 gradient, increased SOX2 spatial heterogeneity, and expansion of SOX2/CD44 double-positive glands. Median SOX2_Gradient shifted from positive values in reflux esophagitis and NDBE to strongly negative values in HGD and EAC_T1a (P < 0.001). SOX2_Tile_Gini and CD44_HScore increased significantly with histologic severity and progression status (both, P < 0.001). Lower SOX2_Gradient, higher SOX2_Tile_Gini, higher CD44_HScore, and longer Prague M length were significantly associated with progression to HGD/EAC. Conclusions: Spatial remodeling of SOX2 expression is strongly associated with dysplasia grade and neoplastic progression in BE. Integration of SOX2 spatial metrics with established biomarkers may improve risk stratification beyond conventional histopathologic assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.